| NOVARTIS PHARMA AG Patent applications |
| Patent application number | Title | Published |
|---|
| 20130040973 | JAK PI3K/mTOR COMBINATION THERAPY - Provided herein is a combination therapy comprising a JAK kinase inhibitor and a dual PI3K/mTOR inhibitor, as well as methods of treating various cancers through the use of such a combination therapy. | 02-14-2013 |
| 20120128728 | Compositions Comprising Amphotericin B - The present invention comprises compositions and formulations comprising amphotericin B comprising less than 10% degradants, compositions and formulations comprising amphotericin B with one or more excipients, methods of making amphotericin B compositions and formulations, as well as systems for using amphotericin B compositions and formulations. Also provided are pharmaceutical compositions comprising the formulation, methods of administering the pharmaceutical compositions and methods of treating patients with the pharmaceutical compositions. | 05-24-2012 |
| 20120114674 | Molecular Antigen Array - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses. | 05-10-2012 |
| 20110070309 | PHARMACEUTICAL FORMULATION COMPRISING A WATER-INSOLUBLE ACTIVE AGENT - A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar than the first solvent and the excipient is more soluble in water than the active agent. The first and second solvents are removed from the solution to produce particles comprising the active agent and the excipient. In one version, the excipient comprises an amino acid and/or a phospholipid. A pharmaceutical formulation made by a version of the invention comprises particles comprising an active agent and an excipient which at least partially encapsulates the active agent, wherein the excipient is more soluble in water than the active agent. | 03-24-2011 |
| 20110008334 | NOGO-A BINDING WITH ENHANCED AFFINITY AND PHARMACEUTICAL USE THEREOF - The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG or human NiG-D20 or human NogoA_342-357 with a dissociation constant, 1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a nerve repair, a pharmaceutical composition comprising said binding molecule; and a method of treatment of nerve repair; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with nerve repair. | 01-13-2011 |
| 20100227833 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS - This invention relates to novel compounds that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections. | 09-09-2010 |
| 20100163021 | SYSTEM FOR DELIVERING NEBULIZED CYCLOSPORINE AND METHODS OF TREATMENT - Systems comprising a pressurized delivery device and a formulation of cyclosporine coupled to an exhalation filter or trap that is capable of preventing cyclosporine from escaping into the local environment are provided. An apparatus for use in the system comprises either an exhalation filter and a pressurized delivery device, wherein the exhalation filter is capable of providing high filter efficiency and maintaining low filter resistance after usage with the formulation, or a trap which provides a means for expired gas to be released into a solvent chamber containing a solvent with a high affinity for cyclosporine. These systems may be used to treat patients with pulmonary disorders, organ transplant patients such as lung transplant patients, and other immune-related disorders. | 07-01-2010 |
| 20100124536 | Hemophilia Treatment by Inhalation of Coagulation Factors - Hemophilia treatment by the inhalation of coagulation factors. Dry powder Factor IX is aerosolized to a mass median aerodynamic diameter of 4 μm or less, with at least 90% monomer content, at least 80% activity level, and 10% water or less. The aerosol is slowly, and deeply inhaled into the lung, and followed by a maximal exhale. | 05-20-2010 |
| 20100034910 | Spray drying process control of drying kinetics - The present invention provides exemplary systems and methods for producing dry powder formulations. In one embodiment, a system ( | 02-11-2010 |
| 20090308384 | Apparatus and methods for delivery of medicament to a respiratory system - Apparatus and methods are provided for delivery of a medicament to a respiratory system. A reservoir is provided for a liquid medicament with the reservoir having a liquid medicament inlet port and a medicament outlet. An aerosol generator is provided at the medicament outlet of the reservoir for aerosolizing the liquid medicament. A connector entrains the aerosolized medicament from the aerosol generator with a gas. | 12-17-2009 |
| 20090260623 | Aeorosolization apparatus with air inlet shield - An aerosolization apparatus comprises a housing defining a chamber having a plurality of air inlets. The chamber contains an aersolizable pharmaceutical formulation or is sized to receive a receptacle which contains an aerosolizable pharmaceutical formulation. A shield covers at least one of the air inlets or a portion of at least one of the air inlets. The shield prevents blockage of the air inlet by a user grasping the apparatus and inadvertently covering the air inlet. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the receptacle. | 10-22-2009 |
| 20090249898 | Systems and methods for non-destructive mass sensing - The invention provides systems and methods for measuring the mass of a substance. In one method, energy is applied to a substance and a response resulting from the application of energy as measured. The mass of the substance is then determined based at least in part on the measured response. | 10-08-2009 |
| 20090246215 | Amyloid beta1-6 antigen arrays - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an Aβ1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one Aβ1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. | 10-01-2009 |
| 20080274131 | Molecular antigen arrary - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses. | 11-06-2008 |
